A Prospective, Open-Label Study Comparing The Cardiac Safety Of The First Dose Of Fingolimod (FTY-Gilenya) Versus Generic Version Of Fingolimod (FTY-Generic) In Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Trial Profile

A Prospective, Open-Label Study Comparing The Cardiac Safety Of The First Dose Of Fingolimod (FTY-Gilenya) Versus Generic Version Of Fingolimod (FTY-Generic) In Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2017 New trial record
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top